| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
CLINICAL REVIEW |
Laboratory for Experimental Medicine and Endocrinology (D.V., K.V., J.O., R.B., S.B.), Leuven University Center for Metabolic Bone Diseases (D.V., R.B., S.B.), and Division of Geriatric Medicine (S.B.), Katholieke Universiteit Leuven, B-3000 Leuven, Belgium
Address all correspondence and requests for reprints to: Dirk Vanderschueren, Laboratory for Experimental Medicine and Endocrinology, Gasthuisberg, Onderwijs and Navorsing, Herestraat 49, B-3000 Leuven, Belgium. E-mail: dirk.vanderschueren{at}uz.kuleuven.ac.be.
Context: Traditionally, differences in periosteal bone formation between men and women have been assumed to reflect two diverging endocrine effects: stimulatory effects of androgens in men and inhibitory effects of estrogens in women. In line with this concept, it is tempting to speculate that men experience more periosteal bone expansion than women because they are exposed to more endogenous androgens and less estradiol. However, recent data challenge this traditional concept.
Evidence Acquisition: A PubMed search was conducted for relevant most recent findings in both humans and animals in the context of an intriguing observation of ongoing periosteal expansion after estrogen treatment in an aromatase-deficient boy.
Evidence Synthesis: Human experiments of nature have provided evidence that androgens and estrogens are both required for the process of pubertal periosteal bone expansion typically associated with the male bone phenotype. Androgens alone appear insufficient to drive male periosteal bone formation. In both sexes, androgens may stimulate periosteal bone formation, but low levels of estrogen may increase the mechanical sensitivity of the periosteum. Higher concentrations of endogenous estrogen, however, inhibit periosteal bone apposition and/or its interaction with mechanical loading. This biphasic action of estrogen on the periosteum may result from a direct effect on its receptor, either
or ß, but may also depend on changes in serum IGF-I.
Conclusions: Simple concepts of the roles of sex steroids in periosteal apposition have to be reconsidered in the context of these recent findings.
This article has been cited by other articles:
![]() |
K. E. Govoni, J. E. Wergedal, R. B. Chadwick, A. K. Srivastava, and S. Mohan Prepubertal OVX increases IGF-I expression and bone accretion in C57BL/6J mice Am J Physiol Endocrinol Metab, November 1, 2008; 295(5): E1172 - E1180. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. P. Smith, B. Specker, B. E. Bachrach, K. S. Kimbro, X. J. Li, M. F. Young, N. S. Fedarko, M. J. Abuzzahab, G. R. Frank, R. M. Cohen, et al. Impact on Bone of an Estrogen Receptor-{alpha} Gene Loss of Function Mutation J. Clin. Endocrinol. Metab., August 1, 2008; 93(8): 3088 - 3096. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Wasilewski-Masker, S. C. Kaste, M. M. Hudson, N. Esiashvili, L. A. Mattano, and L. R. Meacham Bone Mineral Density Deficits in Survivors of Childhood Cancer: Long-term Follow-up Guidelines and Review of the Literature Pediatrics, March 1, 2008; 121(3): e705 - e713. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. H. Windahl, M. K. Lagerquist, N. Andersson, C. Jochems, A. Kallkopf, C. Hakansson, J. Inzunza, J.-A. Gustafsson, P. T. van der Saag, H. Carlsten, et al. Identification of Target Cells for the Genomic Effects of Estrogens in Bone Endocrinology, December 1, 2007; 148(12): 5688 - 5695. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Leger, I. Mercat, C. Alberti, D. Chevenne, P. Armoogum, J. Tichet, and P. Czernichow The relationship between the GH/IGF-I axis and serum markers of bone turnover metabolism in healthy children Eur. J. Endocrinol., November 1, 2007; 157(5): 685 - 692. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |